Cardiac Success develops the Vsling, a transcatheter ventricular repair device designed to reshape the left ventricle in patients with heart failure and reduced ejection fraction. This device addresses the deterioration of cardiac function by initiating therapeutic remodeling, thereby improving symptoms and enhancing patients' quality of life.
Funding
$12.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Heart failure with reduced ejection fraction (HFrEF) affects millions globally, and despite existing therapies, many patients experience a cycle of deterioration due to pathological heart remodeling. Current treatments often fail to directly address the underlying structural issues in the left ventricle.
Solution
Cardiac Success is developing the Vsling, a transcatheter ventricular repair device designed to reshape the left ventricle and initiate therapeutic remodeling in HFrEF patients. The Vsling is delivered via a minimally invasive transcatheter procedure and is adjustable in size to accommodate individual patient anatomy. By directly reshaping the ventricle, the device aims to halt the cycle of deterioration, reduce heart failure symptoms, and improve overall cardiac function. Early clinical findings suggest the Vsling has the potential to improve patients' quality of life.
Target Audience
The primary target audience includes interventional cardiologists and heart failure specialists treating patients with heart failure and reduced ejection fraction (HFrEF) who are seeking minimally invasive solutions to improve cardiac function and quality of life.
Features
- Transcatheter delivery system for minimally invasive implantation
- Adjustable implant size for customized ventricular remodeling
- Atraumatic design to minimize complications during deployment
- Designed to promote therapeutic remodeling and reverse pathological processes
- Intended to directly treat the dilated left ventricle in patients with limited treatment options
- Clinical study inclusion criteria: Ejection Fraction ≥ 20% and ≤ 40%, FMR grade ≤ 2+, NYHA class II-IVa, LV End Diastolic Diameter ≥ 55 mm, Cardiomyopathy of ischemic or non-ischemic origins
- Clinical study exclusion criteria: Prior mitral valve replacement, evidence of structural mitral lesions, severe aortic stenosis, severe tricuspid regurgitation